NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Yirendai Ltd. (NYSE:YRD), Atlantic Capital Bancshares, Inc. (NASDAQ:ACBI), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Sina Corporation (NASDAQ:SINA), Akebia Therapeutics, Inc. (NASDAQ:AKBA), and SMART Global Holdings, Inc. (NASDAQ:SGH), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
YRD DOWNLOAD: http://Fundamental-Markets.com/register/?so=YRD
ACBI DOWNLOAD: http://Fundamental-Markets.com/register/?so=ACBI
JAZZ DOWNLOAD: http://Fundamental-Markets.com/register/?so=JAZZ
SINA DOWNLOAD: http://Fundamental-Markets.com/register/?so=SINA
AKBA DOWNLOAD: http://Fundamental-Markets.com/register/?so=AKBA
SGH DOWNLOAD: http://Fundamental-Markets.com/register/?so=SGH
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Fundamental Markets, available for free download at the links above, examine Yirendai Ltd. (NYSE:YRD), Atlantic Capital Bancshares, Inc. (NASDAQ:ACBI), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Sina Corporation (NASDAQ:SINA), Akebia Therapeutics, Inc. (NASDAQ:AKBA), and SMART Global Holdings, Inc. (NASDAQ:SGH) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 6th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
YIRENDAI LTD. (YRD) REPORT OVERVIEW
Yirendai's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Yirendai reported revenue of $227.54MM vs $131.47MM (up 73.08%) and basic earnings per share $0.75 vs $0.86 (down 13.10%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Yirendai reported revenue of $852.00MM vs $466.37MM (up 82.69%) and basic earnings per share $3.50 vs $2.72 (up 28.70%). Yirendai is expected to report earnings on May 21st, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.84. The estimated EPS forecast for the next fiscal year is $7.40 and is expected to report on March 13th, 2019.
To read the full Yirendai Ltd. (YRD) report, download it here: http://Fundamental-Markets.com/register/?so=YRD
-----------------------------------------
ATLANTIC CAPITAL BANCSHARES, INC. (ACBI) REPORT OVERVIEW
Atlantic Capital Bancshares' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Atlantic Capital Bancshares reported interest income of $25.14MM vs $22.31MM (up 12.69%) and basic earnings per share -$0.61 vs $0.06. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Atlantic Capital Bancshares reported interest income of $96.27MM vs $88.22MM (up 9.13%) and basic earnings per share -$0.15 vs $0.54. Atlantic Capital Bancshares is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.13. The estimated EPS forecast for the next fiscal year is $1.12 and is expected to report on February 4th, 2019.
To read the full Atlantic Capital Bancshares, Inc. (ACBI) report, download it here: http://Fundamental-Markets.com/register/?so=ACBI
-----------------------------------------
JAZZ PHARMACEUTICALS PLC (JAZZ) REPORT OVERVIEW
Jazz Pharmaceuticals' Recent Financial Performance
For the three months ended December 31st, 2017 vs December 31st, 2016, Jazz Pharmaceuticals reported revenue of $436.40MM vs $396.62MM (up 10.03%) and basic earnings per share $3.87 vs $1.94 (up 99.48%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Jazz Pharmaceuticals reported revenue of $1,618.69MM vs $1,487.97MM (up 8.79%) and basic earnings per share $8.13 vs $6.56 (up 23.93%). Jazz Pharmaceuticals is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.41. The estimated EPS forecast for the next fiscal year is $13.94 and is expected to report on February 26th, 2019.
To read the full Jazz Pharmaceuticals PLC (JAZZ) report, download it here: http://Fundamental-Markets.com/register/?so=JAZZ
-----------------------------------------
SINA CORPORATION (SINA) REPORT OVERVIEW
Sina's Recent Financial Performance
For the three months ended September 30th, 2017 vs September 30th, 2016, Sina reported revenue of $443.15MM vs $274.88MM (up 61.22%) and basic earnings per share $0.69 vs $2.08 (down 66.83%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Sina reported revenue of $1,583.88MM vs $1,030.94MM (up 53.64%) and basic earnings per share $2.20 vs $3.20 (down 31.25%). Sina is expected to report earnings on May 15th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.22. The estimated EPS forecast for the next fiscal year is $4.50 and is expected to report on February 12th, 2019.
To read the full Sina Corporation (SINA) report, download it here: http://Fundamental-Markets.com/register/?so=SINA
-----------------------------------------
AKEBIA THERAPEUTICS, INC. (AKBA) REPORT OVERVIEW
Akebia Therapeutics' Recent Financial Performance
For the twelve months ended December 31st, 2017 vs December 31st, 2016, Akebia Therapeutics reported revenue of $177.98MM vs $1.54MM (up 11,495.05%) and basic earnings per share -$1.77 vs -$3.60. Akebia Therapeutics is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$1.15. The estimated EPS forecast for the next fiscal year is -$2.14 and is expected to report on March 11th, 2019.
To read the full Akebia Therapeutics, Inc. (AKBA) report, download it here: http://Fundamental-Markets.com/register/?so=AKBA
-----------------------------------------
SMART GLOBAL HOLDINGS, INC. (SGH) REPORT OVERVIEW
SMART Global's Recent Financial Performance
For the three months ended February 28th, 2018 vs February 28th, 2017, SMART Global reported revenue of $313.97MM vs $171.95MM (up 82.59%) and basic earnings per share $1.68 vs -$0.17. For the twelve months ended August 31st, 2017 vs August 31st, 2016, SMART Global reported revenue of $761.29MM vs $534.42MM (up 42.45%) and basic earnings per share -$0.49 vs -$1.44. SMART Global is expected to report earnings on June 28th, 2018. The report will be for the fiscal period ending May 31st, 2018. The reported EPS for the same quarter last year was $0.54. The estimated EPS forecast for the next fiscal year is $6.51 and is expected to report on September 27th, 2018.
To read the full SMART Global Holdings, Inc. (SGH) report, download it here: http://Fundamental-Markets.com/register/?so=SGH
-----------------------------------------
ABOUT FUNDAMENTAL MARKETS
Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.
REGISTERED MEMBER STATUS
Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com
© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.